Purpose: Tendinopathy risk increases with menopause. The phytoestrogen genistein prevents 4 collagen loss during estrogen deficiency [ovariectomy (OVX)]. The influence of genistein on 5 tendon function and extracellular matrix (ECM) regulation are not well known. We determined 6 the impact of genistein on tendon function and examined potential mechanisms by which genistein 7 alters tendon ECM. Materials and Methods: Eight-week-old rats (n=42) were divided into three 8 groups: intact, OVX, or OVX-genistein (6mg/kg/day) for 6-weeks. Tail fascicles were assessed 9 with a Deben tensile stage. Achilles tendon mRNA expression was determined with digital droplet 10 PCR. Tendon-derived fibroblasts were also treated with genistein in the presence of estrogen 11 receptor (ER) antagonists. Results: Compared to intact, stress tended to be lower in untreated 12 OVX rats (p=0.022). Further, modulus and energy density were greater in genistein-treated rats 13 (p<0.05) compared to intact. Neither OVX nor genistein altered expression of Col1a1, Col3a1, 14 Casp3, Casp8, Mmp1a, Mmp2, or Mmp9 (p>0.05). Compared to intact, Tnmd and Esr1 expression 15 was greater and Pcna and Timp1 expression lower in OVX rats (p<0.05). Genistein treatment 16 returned Tnmd, Pcna, and Timp1 to levels of Intact-Vehicle (p<0.05), but did not alter Scx or Esr1 17 (p>0.05). Several b-catenin/Wnt signaling related molecules were not altered by OVX or genistein 18 (p>0.05). In vitro, genistein blunted cell proliferation but not via ERs. Conclusions: Our findings 19 demonstrate that genistein improves tendon function. Genistein inhibits cell proliferation in vitro 20 but not via ER. The effect of genistein in vivo was predominately on genes related to cell 21 proliferation rather than collagen remodeling. 22 23
INTRODUCTION 26 27
The transition through menopause is a significant risk factor for tendinopathies (tendon 28 pain/degeneration), an understudied clinical problem (Abate et al. 2014) . Menopause also leads to 29 deteriorations in tendon function (Frizziero et al. 2014) , changes that likely contribute to the global 30 decline in musculoskeletal function associated with menopause (Nedergaard et al. 2013 ). Overall, 31 tendon alterations during menopause contribute to significant physical impairment, reduced 32 quality of life, and high socio-economic costs (Hopkins et al. 2016) . Although it is unclear if the 33 loss of estrogen with menopause is the primary reason for alterations in tendon properties, estrogen 34 appears to be vital for maintenance of tendon extracellular matrix [ECM; (Cook et Specifically, we have shown that in a rat model of estrogen deficiency [ovariectomy (OVX)], 37 estrogen loss results in a large decline in tendon collagen content (Ramos et al. 2012) , the primary 38 structural protein of tendon. Further, in tendon cell culture, estrogen deficiency results in decreased 39 cell proliferation, reduced type I collagen (Torricelli et al. 2013) , and altered tendon metabolism 40 and healing more than attributable to aging alone (Torricelli et al. 2013) . Estrogen loss may also 41 lead to increased activity of ECM degrading enzymes (Pereira et al. 2010 ). Tissue collagen content 42 directly correlates with tissue stiffness (Ducomps et al. 2003) , implying that a reduction in tendon 43 collagen could contribute to a reduction in tendon functional properties. However, the impact of 44 estrogen loss on tendon functional properties has not been extensively studied (Circi et al. 2009 ). 45
Further, the molecular mechanisms modulating the effects of estrogen on tendon are not well 46 defined. 47 A common therapeutic choice for estrogen-deficiency, primarily postmenopause, is estrogen 48 therapy (ET). However, in postmenopausal women ET is associated with tendons that have a lower 49 Young's modulus and a greater number of smaller collagen fibrils (Hansen, Kongsgaard, et al. 50 2009 ). ET also limits tendon hypertrophy with exercise in postmenopausal women (Cook et al. 51 2007; Finni et al. 2009 ). Moreover, it has been suggested that tendinopathy is more common with 52 ET compared to no ET (Holmes and Lin 2006) . Collectively, these findings suggest that alternative 53 approaches to minimizing the impact of estrogen loss on tendon are needed. 54
Genistein, a plant-derived, naturally occurring isoflavone phytoestrogen found in soy, may be 55 a useful strategy to reduce the effects of estrogen deficiency on tendons (Ramos et al. 2012) . 56
Genistein is thought to convey many of the health benefits associated with a diet high in soy, 57 including improved bone mass (Marini et al. 2007 ; Qi and Zheng 2017), reduced breast cancer risk 58 (Trock et al. 2006; Verheus et al. 2007) , and reduced risk of cardiovascular disease (Squadrito et 59 al. 2003) . The beneficial effects of genistein on bone and cardiovascular disease remain 60 controversial (Abdi et al. 2016 ), but in an OVX rat model we demonstrated that genistein reverses 61 the decline in tendon collagen associated with the loss of estrogen (Ramos et al. 2012) . However, 62 the mechanisms by which genistein modulates ECM have not been explored and it is unclear if 63 genistein can improve tendon mechanical properties in estrogen deficient rats. The objectives of 64 this investigation were to: 1) determine if genistein can improve tendon functional properties in 65 estrogen deficient rats, and 2) examine the impact of estrogen loss and genistein supplementation 66 on key regulators of ECM that could account for the changes in tendon collagen noted in our 67 previous work (Ramos et al. 2012 The chosen dose of genistein was designed to represent a human diet high in soy, which has been 79 associated with lower rates of breast and prostate cancer (Tham et al. 1998 ) and modest changes 80 in risk factors for cardiovascular disease and osteoporosis (Anderson et al. 1998 ) without effects 81 on endometrial thickness (Alekel et al. 2014 ). Doses were scaled to a rat equivalent (Services 82 2005). Rats were studied in two separate cohorts with 18 rats (6 per group) in cohort 1 and 24 rats 83 (8 per group) in cohort 2. Tail tendon fascicle mechanical properties were evaluated in all rats; 84 however, tendons from cohort 1 were used for a separate set of RNA sequencing experiments. 85
Thus, gene expression data is reported from eight rats per group. 86
After group assignment, rats were caged in pairs (with each pair being members of the same 87 experimental group), allowed access to genistein-free food (Modified AIN-93G with Corn Oil,  88 Dyets Inc, Bethlehem, PA), water ad libitum, and maintained on a 12-hour light-dark cycle. After 89 a two-week equilibration period, rats were treated with genistein or vehicle daily for six weeks. 90
After six weeks, rats were euthanized by decapitation after CO2 inhalation (Ramos et al. 2012) . 91
Tendons were carefully dissected from the rats, removed of any excess fascia and muscle, flash 92 frozen in liquid nitrogen, and transferred to -80°C. Tails were immediately removed, wrapped in 93 saline soaked gauze, and stored at -20°C until analysis. This investigation was approved by the 94 Purdue University and Midwestern University Institutional Animal Care and Use Committees and 95 all animals were cared for in accordance with the recommendations in the Guide for the Care and 96
Use of Laboratory Animals (Council 2011) . 97
Achilles Tendon Gene Expression 98
Total RNA for gene expression analysis was isolated from the Achilles tendon as previously 99 described (Patel et al. 2018) . Briefly, 10 to 20 mg of frozen tendon tissue was pulverized under 100 cryogenic conditions (OPS Diagnostics, Lebanon, NJ) and lysed using a bead mill homogenizer 101 (BR12, Omni) in TRIzol Reagent (Invitrogen). Phase separation and RNA precipitation were 102 completed per the manufacturer's instructions (TRIzol, Invitrogen). RNA concentration was 103 determined using a NanoDrop 2000 (Thermo Fisher Scientific). Quality of RNA was assessed 104 using the 260/280 and 260/230 ratios. Reverse transcription (iScript, BioRad, Hercules, CA) was 105 completed to produce complementary DNA from 100ng of RNA. Absolute quantification of 106 mRNA target transcripts was completed using digital droplet PCR (ddPCR; BioRad) and reported 107 as positive counts per 20µl reaction (Patel et al. 2018 ). Input cDNA for all genes was 1.11 ng, 108 excluding Col1a1, Col3a1, Tnmd, and Dcn, which were 0.55 ng. 109
Tail Tendon Fascicle Mechanical Properties 110
Tail fascicles (~30 mm in length) were harvested and their mechanical properties were assessed 111 as previously described (Volper et al. 2015) . Briefly, we used a Deben mini tensile tester 200 N 112 stage (Deben, UK, Ltd.) and a Nikon SMZ1000 microscope with a color C-mos chip 1280×1024 113
Pixelink camera attached for sample imaging. Tensile force was applied by increasing the distance 114 between the clamps at 1mm/min from resting (0.20 N) to ~0.25 N. Ten cycles for pre-conditioning 115 were performed during which fascicles were subjected to 3% deformation from resting length. 116
Following pre-conditioning, images were captured from the top and side for calculation of cross-117 sectional area and tendon fascicle length at the onset of force (0.01-0.05 N) with fascicle crimps 118 evaluated to be intact. Sample mechanical properties were then determined by increasing the 119 distance between the clamps at 6 mm/min until sample failure while recording force data at 10 Hz. 120
Force and dimension data were subsequently used to calculate maximum force, maximum stress, 121 and Young's modulus, each of which were determined as the peak value of a moving linear 122 regression over 10 data points. 123
Histology 124
Immersion-fixed (Histo-choice Fixative D, Amresco) longitudinal sections of the Achilles 125 tendon were dehydrated through graded methanol, cleared with toluene, and embedded in paraffin 126 (Formula R, Leica Microsystems Surgipath, Buffalo Grove, IL) (Volper et al. 2015) . Sections (4 127 µm) were dewaxed and rehydrated through graded ethanol and stained with hematoxylin and eosin 128 (H&E) staining to determine cell density (Volper et al. 2015) . Cell counting was completed 129 independently by two investigators. 130
Cell Culture 131
Tendon-derived fibroblasts were isolated from the Achilles tendon of four rats from the Intact 132 group. After euthanasia, tendon was rinsed with sterile PBS, finely minced, placed in DMEM 133 containing 0.2% type I collagenase, and incubated in a 37°C shaking water bath for four hours. 134
After tissue digestion, the cell suspension was filtered through a 100µm mesh filter, pelleted by 135 centrifugation, resuspended in 5.5mM glucose DMEM containing 10% FBS, 1% sodium pyruvate 136 (Sigma), and 1% penicillin/streptomycin (Thermo Scientific) and plated in 100mm collagen coated 137 dishes. After reaching ~75-80% confluence, tendon fibroblasts were seeded with media containing 138 DMSO vehicle, genistein (150 µM, LC Laboratories), or estradiol (1.1 µM, Sigma-Aldrich) and 139 were treated with control, MPP (100 µM, Sigma-Aldrich), or PHTPP (1000 µM, Sigma-Aldrich) 140 for 48 hours. Tendon fibroblasts from passage 2-4 were used for all experiments. Cell counts were 141 completed in duplicate using a hemocytometer. 142
Statistical Analysis 143
Our statistical analyses on contrasts between the Intact-Vehicle, OVX-Vehicle, and OVX-144
Genistein groups proceed via two classes of regression models. Normal linear regression models 145 were fit for the tendon gene expressions data, and mixed effects regression models were fit for the 146 tail fascicle mechanical properties and body weight data. The independent variables that were 147 considered for all of the regression models were indicators for the two OVX groups, with the intact 148 group serving as the baseline. Further details on the specific regression analyses that were 149 performed for these three types of dependent variables are provided in the following subsections. 150
Regression Analysis for Tendon Gene Expressions: Separate Normal linear regression models 151
were fit for each individual gene using the lm function in the statistical software environment R. 152 For each fitted model, we checked whether the standard assumptions for linear regression were 153 satisfied on the original scale of the dependent variable. If so, we then performed tests for all 154 pairwise contrasts between the three groups using the regression parameters' estimators and 155 standard errors. If the assumptions were not satisfied, we then considered a Normal linear 156 regression model on the square root scale of the dependent variable (which is a standard variance-157 stabilizing transformation for the count data inherent in gene expressions), as well as weighted 158 linear regression models on both the original and square root scales. We then determined which of 159 these latter three models provided the best fit to the data in terms of satisfying the regression 160 assumptions. Once a final model was selected, we proceeded to perform tests for all of the pairwise 161 contrasts. Our chosen significance level was α = 0.05 throughout, and we accounted for the 162 multiple comparisons among the three groups by means of separate Bonferroni adjustments across 163 the genes. 164
Mixed Effects Regression Modeling for Mechanical Properties: Separate mixed effects regression 165
models were fit for each mechanical property using the lmer function in the lme4 package in R. 166
As the mechanical properties data were collected from two distinct cohorts of rats, each model had 167 two sets of fixed effects that correspond to the OVX and cohort groups, and one set of random 168 effects that correspond to unique, random intercepts for the rats. These intercepts are assumed to 169 be independent Normal random variables with mean 0 and identical variance. This specification 170 of a single model with fixed and random effects can effectively account for the expected 171 correlation in the properties of the two fascicles that were extracted from one rat, as well as possible 172 differences that arise across the cohorts. 173
The analysis for each property proceeds via consideration of two mixed effects regression 174 models, referred to as the "main effects" and "full" models, respectively. Both have fixed effects 175 for cohort, OVX-Vehicle, and OVX-Genistein, and random intercepts for the rats. However, the 176 full model considers interactions between cohort and OVX, whereas the main effects model does 177 not. We first tested the significance of the interactions in the full model. If any interaction is 178 statistically significant we selected the full model, whereas if no interaction is statistically 179 significant we selected the main effects model. In either case, we diagnosed the validity of the 180 assumptions for the selected mixed effects regression model. If the assumptions were satisfied, we 181 tested all three pairwise main effect contrasts for the treatments. If the assumptions were not 182 satisfied, we performed the same type of mixed effects regression analyses described above on the 183 logarithmic-transformed dependent variable. As before, our chosen significance level was α = 0.05 184 throughout, with a Bonferroni correction made to adjust for the fact that we are testing three 185 contrasts. 186
Mixed Effects Longitudinal Regression Modeling for Body Weight: A mixed effects longitudinal 187
regression model was fit for the rat body weight data using the lmer function in the lme4 package 188 in R. The body weights were collected on the previously described two cohorts of rats. As body 189 weight is a positive, continuous measurement, we fitted the mixed effects model on the 190 logarithmic-transformed weights to better satisfy the regression assumptions. On the basis of 191 exploratory data analyses and visualizations, we compared two mixed effects regression model 192 specifications to determine how rat body weight depends on the different treatments and cohorts, 193 and changes across time: a "full" model that incorporates fixed main effects and two-factor 194 interactions for OVX groups, cohort, and time, and a "reduced" model that incorporates fixed main 195 effects and two-factor interactions only for OVX groups and time. In both of these models, a 196 random intercept and a random slope for time is introduced for each rat. These random effects are 197 specified to capture observed variations in linear time trends and intercepts between rats. The 198 validity of the assumptions for the mixed effects longitudinal regression models were assessed via 199 residual diagnostics. After fitting these two mixed effects regression model, we tested the 200 significance of the interactions and determined whether the reduced model was sufficient for 201 explaining the observed trends in the body weight data. Finally, we tested the fixed effects for the 202 selected regression model. 203
204

RESULTS
205
Body mass increased with time in all groups but rats in the OVX groups were heavier than 206 intact rats (p<0.05, Figure 1 ). Tendon tail fascicle stiffness was not altered by OVX or genistein 207 treatment (p>0.05, Table 2 ). Deformation (p=0.048), maximum stress (p=0.022) and yield stress 208 (p=0.052) tended to be lower in OVX-Vehicle rats when compared to Intact-Vehicle but failed to 209 reach statistical significance after correction for multiple comparisons (adjusted a=0.017, Table  210 2). In contrast, energy density at yield, modulus, maximum stress, and yield stress were greater in 211 OVX-Genistein rats when compared to OVX-Vehicle (p<0.05, Table 2 ). 212 Table 3 provides rats when compared to OVX-Vehicle, but still higher than Intact-Vehicle (p<0.05, Figure 4) . 230
Further, Pcna expression was 33% lower in OVX-Vehicle (563±20) in comparison to Intact-231 Vehicle (787±57, p<0.05) whereas the reduction was prevented by genistein treatment (Figure 4 In our previous work, we demonstrated that loss of estrogen due to OVX leads to a large decline 259 in rat Achilles tendon collagen, an effect that is prevented by administration of genistein (Ramos 260 et al. 2012 ). In the current investigation, we follow-up on these findings by determining the impact 261 of OVX and genistein treatment on tendon functional properties, while also exploring the effects 262 of OVX and genistein on tendon ECM regulators and cell proliferation. In line with our Achilles 263 tendon collagen findings (Ramos et al. 2012 ), tendon fascicle failure stress tended to be lower after 264 OVX and genistein treatment led to higher failure stress. Tendon fascicle modulus and energy 265 density were also modestly higher in OVX genistein treated rats. Surprisingly, even with the large 266 loss of Achilles tendon collagen noted in our previous work (Ramos et al. 2012), we did not 267 observe an effect of OVX or genistein on Achilles tendon Col1a1 or Col3a1 expression. Further, 268 key genes associated with ECM degradation were not altered by OVX or genistein treatment. We 269 did, however, observe a modest increase in Dcn expression, a proteoglycan involved with 270 regulating collagen fibril formation and inhibiting cellular proliferation (Yoon and Halper 2005) , 271 with genistein treatment. Although no effect of OVX or genistein on the expression of Wnt 272 pathway associated genes was noted, we did observe significant effects of OVX and genistein on 273 Tnmd and Pcna expression, which are key modulators of cellular proliferation (Dex et al. 2016) . 274
Interestingly, neither OVX nor genistein altered cell counts when evaluated by H&E staining but 275 genistein did suppress cell proliferation in vitro. Further, the effect of genistein on cell proliferation 276 in vitro did not appear to require estrogen receptor signaling. Based on our gene data, we 277 hypothesize that the effects of OVX and genistein on tendon collagen may be driven more by 278 changes in cellular proliferation genes rather than direct effects on expression of ECM-related 279 genes. Future studies with more specific measures of cellular proliferation and enzyme activity are 280 needed to further investigate this hypothesis. 281
Collagen is the primary protein constituent of tendon and correlates strongly with tissue 282 mechanical properties (Ducomps et al. 2003) . Therefore, it seemed likely that tendon fascicle 283 mechanical properties would be impaired in OVX rats, given our previous report demonstrating a 284 large loss of tendon collagen with OVX (Ramos et al. 2012) . Consistent with limited previous 285 studies (Circi et al. 2009 ), tendon fascicle failure stress tended to be lower after OVX. Genistein 286 treatment also resulted in higher modulus and energy density when compared to untreated OVX 287 rats. However, we did not observe effects on several other critical functional variables such as 288 stiffness. Changes in tendon stiffness can alter musculoskeletal performance during functional 289 activities (Bojsen-Moller et al. 2005), but our findings suggest that loss of estrogen may not alter 290 tendon function under submaximal loading conditions. Importantly, genistein administration, at 291 amounts easily obtained in the diet, was effective at preserving tendon fascicle failure stress to 292 similar levels as those of intact rats. Our findings provide preclinical evidence that genistein, at 293 doses that can be easily obtained from dietary consumption, may be useful for minimizing the 294 impact of estrogen loss on tendon functional properties. The conclusions of our mechanical 295 findings should be considered with some caution as we are comparing our tail tendon fascicle 296 findings to our previous collagen work in the Achilles tendon (Ramos et al. 2012) . 297
A second objective of the current investigation was to further develop our understanding of the 298 mechanisms mediating the effects of estrogen loss and genistein on tendon. Given the large decline 299 in total tendon collagen noted previously (Ramos et al. 2012 ), we first examined the impact of 300 OVX and genistein on Col1a1 and Col3a1 expression as well as expression of the proteoglycans 301 decorin and betaglycan (Tgfbr3). Surprisingly, we did not observe an effect of OVX or genistein 302 on the expression of collagen genes. This finding suggests that changes in collagen content due to 303 OVX or genistein may be mediated by post-translational modifications of collagen synthesis or 304 breakdown rather than alteration of gene transcription. Specific studies directly assessing collagen 305 synthesis and related signaling pathways would provide further insight. 306
Although betaglycan expression was not altered by either OVX or genistein, Dcn expression 307 was higher in OVX-Genistein treated rats relative to OVX-Vehicle. Dcn is the most abundant 308 proteogylcan in tendon and a highly expressed transcript (Table 3) Interestingly, we noted an increase in Esr1 expression after OVX, an effect that was not 348 normalized by genistein treatment. Work in other tissues observed an increase in Esr1 expression 349 after OVX, albeit tissue specific (Mohamed and Abdel-Rahman 2000) . Furthermore, using 350 validated Esr2 probes (Biorad), we were not able to detect expression of Esr2 transcripts in the 351 Achilles. We have also noted no expression of Esr2 in the Achilles tendon using RNA sequencing 352 (unpublished observation). In contrast, others have reported the presence of Esr2 protein in tendon-353 derived cells with greater expression after OVX (Hsieh et al. 2018 ). Our ddPCR findings suggest 354 that the effects of estrogen on tendon may rely on Esr1 rather than Esr2. This conclusion was 355 confirmed in our in vitro model where estradiol treatment increased cell proliferation but not when 356 cells were concurrently treated with an ER-a (Esr1) antagonist. ER-b antagonism did not prevent 357 estradiol induction of cell proliferation, which is consistent with previous in vitro findings (Maman 358 et al. 2016 ). Additionally, genistein reduced cell proliferation in vitro but, surprisingly this effect 359 did not seem to require activation of ER-a or ER-b. Genistein is an estrogen receptor agonist and 360 has a much greater affinity for ER-b (Kuiper et al. 1998) . Our data suggest that tendon may lack 361 ER-b (Esr2) and that genistein may modulate tendon collagen and ECM gene expression via non-362 estrogenic pathways. 363
Of note, ddPCR technology allows for absolute quantification of mRNA transcripts with a 364 detection limit of a single transcript. Although the relationship between overall transcript 365 expression in a tissue and the importance of a gene to tissue cellular function is not clear, our 366 ddPCR data (Table 3) does provide an interesting observation regarding tenocyte "commitment" 367 to generating transcripts for a specific gene. As might be expected, the number of collagen and 368 decorin transcripts were considerably higher than the other genes evaluated. Interestingly, Intact 369 rats, genes such as Tnmd and Scx were expressed at a level of ~50-250 fold less than Col1a1. 370 Expression of Mmp9, an important modulator of ECM breakdown, that has been examined in 371 several tendon related studies, was surprisingly very low. 372
In conclusion, we demonstrate that OVX lead to a decline in stress at tendon fascicle failure 373 but other important functional variables (e.g. stiffness) were not impacted. We can also conclude 374 that genistein can reverse the effects of OVX on tendon fascicle failure stress. Even though we 375 previously observed a large reduction in tendon collagen content after OVX (Ramos et al. 2012 ), 376 our current findings infer that these changes may, in part, be modulation of Tnmd and Pcna rather 377 than collagen genes or expression of ECM degrading proteins. Further, our findings suggest that 378 genistein, although shown to have an affinity for estrogen receptors, does not completely reverse 379 the effects of estrogen loss on the expression of several genes in the rat Achilles tendon and does 380 not require estrogen receptors to impact tendon fibroblast proliferation. Future studies, should 381 examine the impact of combined estrogen and genistein supplementation and included protein 382 measures and evaluation of estrogen receptor activation. 383 
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